Standard 1-Hour Pad Test Has Limited Value
Monday, 27 September 2004
BERKELEY, CA (UroToday Inc.) - The 1-hour pad test has been used as an objective tool in studying women with urinary incontinence (UI).
read more
|
Sexual Function Declines after Surgery for Stress Urinary Incontinence.
Tuesday, 31 August 2004
BERKELEY, CA (UroToday Inc.) - Urinary incontinence can significantly impact quality of life (QOL). Surgical treatment improves this QOL.
read more
|
Severity of Incontinence and History of Prior Treatment Impacts the Placebo Response of Studies of Stress Urinary Incontinence
Friday, 27 August 2004
BERKELEY, CA (UroToday Inc.) - The placebo response in trials for stress urinary incontinence (SUI) can be quite marked.
read more
|
Overactive Bladder Found to be Intimately Associated With Stress Incontinence and Increased Body Mass Index in Middle-Aged Women
Monday, 19 July 2004
BERKELEY, CA (UroToday Inc.) -
Female urinary incontinence has been traditionally described and divided by that which occurs in relation to physical exertion (stress urinary incontinence or SUI) and that which is preceded by the presence of the urge to void (urge incontinence).
read more
|
FDA Approves Indevus's Overactive Bladder Drug
Monday, 31 May 2004
NEW YORK (Reuters) - Indevus Pharmaceuticals Inc. said on Friday that U.S. regulators approved its experimental drug for overactive bladder.
read more
|
Once-Daily Oxybutynin, Tolterodine Reduce Incontinence in Women With Overactive Bladder
Monday, 23 June 2003
NEW YORK (Reuters Health) - Extended-release oxybutynin and tolterodine are similarly effective for reducing urge urinary incontinence (UUI) and total incontinence episodes in women with overactive bladder, according to a report in the June issue of Mayo Clinic Proceedings.
read more
|
Data Presentations Support Efficacy and Tolerability of OXYTROL(TM) (Oxybutynin Transdermal System) in Treating Women Suffering From Symptoms of Overactive Bladder
Wednesday, 30 April 2003
NEW ORLEANS, April 30 /PRNewswire/ -- OXYTROL(TM) (oxybutynin transdermal system) is effective, well tolerated, and significantly reduces the number of incontinent episodes associated with overactive bladder (OAB) with a low incidence of anticholinergic side effects, according to three presentations given today during the annual meeting of the American College of Obstetricians and Gynecologists (ACOG).
read more
|
Nerve Growth Factor and Detrusor Overactivity is There a Physio-Pathogenetic Correlation?
Tuesday, 29 April 2003
TUESDAY, APRIL 29, 2003 (AUA) - Introduction and Objective: Steers & Tuttle in animals and Tanner in humans, showed that chronic bladder outlet obstruction(BOO) causes NGF hyperexpression secondary to the afferent neurons plasticity induced by bladder hypertrophy and that NGF expression increases in idiopathic unstable bladder patients(pts).
read more
|
Watson Pharmaceuticals' (WPI) OXYTROL Now Available Nationwide; Shipments To More Than 45,000 Pharmacies
Monday, 28 April 2003
CORONA, Calif., April 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that OXYTROL(TM) (oxybutynin transdermal system), the first and only transdermal therapy to treat overactive bladder (OAB), with symptoms of urge urinary incontinence, urgency and frequency, is now available nationwide, having shipped to more than 45,000 major pharmacy chain and independent stores.
read more
|
Increasing Oxybutynin Dose Improves Overactive Bladder Control
Friday, 04 April 2003
WASHINGTON, DC (Reuters Health) - Applying more oxybutynin patches increases the plasma concentration and improves overactive bladder control, according to research presented at the 2003 Annual Meeting of the Society for Clinical Pharmacology and Therapeutics here.
read more
|
Incontinence Drug Sales Soar
Tuesday, 04 March 2003
TUESDAY, MARCH 04, 2003 (Post Gazette) A multimillion-dollar marketing campaign featuring those "gotta go" TV spots helped quadruple sales of Detrol two years after the drug for overactive bladders was introduced to the U.S. market in 1998. Worldwide, sales increased sixfold.
read more
|
FDA Approves Watson's Oxytrol TM, First and Only Transdermal Therapy for Overactive Bladder
Wednesday, 26 February 2003
Corona, Calif. - February 26, 2003 - Watson Pharmaceuticals, Inc. (NYSE: WPI), announced today that the U.S. Food and Drug Administration (FDA) has approved OXYTROL tm (oxybutynin transdermal system), the first and only transdermal therapy to treat overactive bladder (OAB), with symptoms of urge urinary incontinence, urgency and frequency.
read more
|
Overactive Bladder
-
read more
|
Overactive Bladder (OAB) 
